Lexpert Special Editions

30 www.lexpert.ca Big Deals COMPILED BY ZENA OLIJNYK AND BERNISE CAROLINO NEPTUNE WELLNESS SOLUTIONS INC. CLOSING OF US$55-MILLION REGISTERED DIRECT OFFERING CLOSING DATE: FEB. 17, 2021 Neptune Wellness Solutions Inc., a diversi- fied and fully integrated health and wellness company focused on natural, plant-based, sustainable and purpose-driven lifestyle brands, entered into definitive agreements with institu- tional investors for the purchase of 27.5 million common shares and issued to the investors, in a concurrent private placement, unregistered common share purchase warrants to purchase an aggregate of 6,875,000 common shares for aggregate gross proceeds of approximately US$55 million before deducting fees and other estimated offering expenses. A.G.P./Alliance Global Partners is acting as sole placement agent for the offering. Fasken Martineau DuMoulin LLP acted as legal counsel to Neptune in connection with this offering with a team composed of Krisztian Toth, Peter Villani and Oleg Stratiev. PLANET 13 HOLDINGS INC. CLOSING OF $69 MILLION BOUGHT DEAL PUBLIC OFFERING CLOSING DATE: FEB. 2, 2021 Planet 13 Holdings Inc. announced that it has closed a bought deal prospectus offering for aggregated gross proceeds of $69,028,750. A total of 9,861,250 units of Planet 13 Holdings Inc. were sold pursuant to the offering, including an aggregate of 1,286,250 units issued as a result of the full exercise of the underwriters' over-allotment option, at a price of $7 per unit. Beacon Securities Limited and Canaccord Genuity Corp. (collectively, the "Underwriters") co-led the offering. Each unit consists of one common share in the capital of Planet 13 Holdings Inc. and one-half of one common share purchase warrant. Each whole warrant entitles the holder thereof to acquire one common share at an exercise price of $9 per common share for a period of 24 months following the closing of the offering. e Underwriters received a cash commission equal to six per cent of the gross proceeds from the sale of the units pursuant to the offering and compensation options equal to six per cent of the number of units sold pursuant to the offering. Each compen- sation option entitles the Underwriters to purchase one common share at a price of $7 for a period of 24 months following closing. Fasken Martineau DuMoulin LLP advised the Underwriters in connection with the offering with a team led by Rubin Rapuch, and which included Bradley Freelan, Markus Liik, Allison Marks, Jordana Keslassy, Gurinder (Gigi) Gujral, and Arie van Wijngaarden. KARDIUM INC. COMPLETION OF US$115-MILLION SERIES D FINANCING ROUND CLOSING DATE: JAN. 25, 2021 Kardium Inc., based in Vancouver, announced that it had raised US$115 million in a new financing round led by Fidelity Management & Research Company LLC, together with other follow-on participation funds and accounts advised by T. Rowe Price Associates, Inc. Kardium announced that the new finan- cing would be used to accelerate commer- cial growth of its Globe® Mapping and Ablation System in order to offer innovative atrial fibrillation treatment for millions of patients worldwide. e investment allows the company to accelerate commercial sales in Europe, as well as to begin the FDA clin- ical study for the Globe System. Fasken Martineau DuMoulin LLP advised Kardium Inc. with a team led by Shahrooz Nabavi (corporate/commercial and corporate finance), and which included Iain Mant (securities), Mike Coburn (tax), Geoff Pedlow, Katie Peardon and Rasmeet Mohar (corporate/commercial and corporate finance). THERATECHNOLOGIES INC. CLOSING A US$46 MILLION BOUGHT DEAL PUBLIC OFFERING CLOSING DATE: JAN. 19, 2021 eratechnologies Inc., a biopharmaceut- ical company focused on the development of innovative therapies that address unmet medical needs of HIV patients, closed a bought-deal public offering pursuant to which eratechnologies issued 16,727,900 units at a price of US$2.75 per unit (equiva- lent to approximately $3.51 per unit) for aggregate gross proceeds of US$46,001,725 (equivalent to approximately $58,714,929), including the full exercise of the over-al- lotment option to purchase an additional 2,181,900 units at the offering price. Mackie Research Capital Corporation, as the lead underwriter and sole bookrunner, led the offering on behalf of a syndicate of underwriters, including Canaccord Genuity Corp. and National Bank Financial Inc. Fasken Martineau DuMoulin LLP acted as legal counsel to eratechnologies in connection with this offering with a team composed of Jean-Pierre Chamberland, Oleg Stratiev (corporate), Ryan Rabinovitch and Andrew Haikal (tax). HAVN LIFE SCIENCES INC. COMPLETION OF $11.5-MILLION BOUGHT DEAL FINANCING COMPLETION DATE: JAN. 7, 2021 On Jan. 7, HAVN Life Sciences Inc. ("Havn") completed a bought deal public > HEALTH SCIENCES DEALS

• Cover